Logo do repositório
 
Publicação

Do novel European Headache Federation criteria identify differences in migraine burden?: baseline data of an international real-life study on resistant and refractory migraine (REFINE)

dc.contributor.authorCaponnetto, V.
dc.contributor.authorOrnello, R.
dc.contributor.authorRosignoli, C.
dc.contributor.authorSantis, N. de
dc.contributor.authorBayar, D.
dc.contributor.authorBraschinsky, M.
dc.contributor.authorCarnovali, M.
dc.contributor.authorGentile, M.
dc.contributor.authorGil-Gouveia, R.
dc.contributor.authorIaccarino, G.
dc.contributor.authorLeheste, A. R.
dc.contributor.authorMartelletti, P.
dc.contributor.authorMazzanti, C.
dc.contributor.authorMunoz-Vendrell, A.
dc.contributor.authorOliveira, R.
dc.contributor.authorOzge, A.
dc.contributor.authorMartins, I. Pavão
dc.contributor.authorPozo-Rosich, P.
dc.contributor.authorPrudenzano, M. P.
dc.contributor.authorRyliskiene, K.
dc.contributor.authorRio, M. S. del
dc.contributor.authorVainauskiene, J.
dc.contributor.authorVernieri, F.
dc.contributor.authorKatsarava, Z.
dc.contributor.authorSacco, S.
dc.date.accessioned2023-02-01T10:47:14Z
dc.date.available2023-02-01T10:47:14Z
dc.date.issued2022-12-07
dc.description.abstractQuestion. We evaluated if EHF criteria for resistant (RES) and refractory (REF) migraine identify patients with more severe migraine burden. Methods. We performed an observational, multi center, international study to compare baseline characteristics, comorbidities, and PROMs of non-resistant and non-refractory (NRNR) migraine, RES and REF individuals in the REFINE study. Results. We included 175 individuals with NRNR migraine, 133 (39.7%) with RES and 27 (8.0%) with REF. Individuals with RES and REF migraine as compared to those with NRNR reported higher monthly migraine days (median=8, IQR=5-14 vs. median=13, IQR=10- 17 and median=15, IQR=10-20; p≤0.001), months of chronification (median=24, IQR=12-72 vs. median=40, IQR=12-108 and median=60, IQR=18-96; p=0.044), monthly days of symptomatic drugs assumption (median=8, IQR=5-15 vs. median=12, IQR=9-20 and median=15, IQR=10-20; p≤0.001), medication overuse (19.4% vs. 45.9% and 40.7%; p≤0.001). They also had more comorbidities such as depression (18.3% vs. 31.1% and 44.4%; p=0.002) and anxiety (13.7% vs. 21.1% and 37%; p=0.009). In these groups, PROMs also revealed a higher presence of anxiety (p≤0.001) and depression (p≤0.001) symptoms and poorer sleep quality (p=0.006). Regarding specific perceptions about migraine, RES and REF individuals reported higher impact of migraine on daily life (p≤0.001) and work, household work, and social life (p≤0.001), along with a lower perception of the effectiveness of their ongoing treatment for migraine (p≤0.001), when compared to NRNR subjects (Table 1). Conclusion. RES and REF migraine is associated with relevant migraine burden considering migraine features, comorbidities and scores at several scales; the severe burdensome condition of RES and REF is confirmed by the median number of monthly migraine days and PROMs.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.issn1129-2369
dc.identifier.urihttp://hdl.handle.net/10400.14/40067
dc.identifier.wos000902020900042
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.titleDo novel European Headache Federation criteria identify differences in migraine burden?: baseline data of an international real-life study on resistant and refractory migraine (REFINE)pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage17pt_PT
oaire.citation.issueSUPPL 1pt_PT
oaire.citation.startPage16pt_PT
oaire.citation.titleJournal of Headache and Painpt_PT
oaire.citation.volume23pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
62023793.pdf
Tamanho:
494.12 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.44 KB
Formato:
Item-specific license agreed upon to submission
Descrição: